tetano
Editor, Senior Moderator
Cureus
. 2022 Feb 16;14(2):e22290.
doi: 10.7759/cureus.22290. eCollection 2022 Feb.
COVID-19-Associated Autoimmune Disease: A Rare First Case Report of Acute Motor Axonal Neuropathy Variant of Guillain-Barre Syndrome in a Woman Patient in New York City
Zaheer Qureshi[SUP] 1 2 [/SUP], Sameer Kandhi[SUP] 2 [/SUP], Neeti Prasai[SUP] 2 [/SUP], Faryal Altaf[SUP] 2 [/SUP], Manjeet Dhallu[SUP] 3 [/SUP]
Affiliations
Abstract
Novel outbreaks with COVID-19 can cause multiple systemic manifestations, including autoimmune disease. Among all the infections, respiratory complications are the most apparent symptoms. Guillain-Barre syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy often related to previous infectious exposure. GBS emerged as a potentially severe complication of coronavirus disease 2019 (COVID-19) since its declaration as a global pandemic. We report the first case of COVID-19-induced acute motor axonal neuropathy variant of Guillain-Barre syndrome (GBS) from New York, USA. Our patient was a 66-year-old woman who had recently tested positive for COVID-19 and presented with bilateral upper and lower extremity weakness. Electromyogram studies showed acute demyelinating polyradiculoneuropathy. She was diagnosed with an acute motor axonal neuropathy variant of GBS. She was successfully treated with intravenous immunoglobulins (IVIGs) with marked improvement. In six months, she regained her strength back to normal. Whether GBS incidence in COVID-positive patients is based on molecular mimicry or anti-ganglioside antibodies is unclear. Physicians should be aware of GBS as a potentially serious complication associated with COVID-19. Further investigations and trials should be conducted better to understand the mechanism of GBS in patients of COVID-19.
Keywords: autoimmune; axonal neuropathy; coronavirus; covid-19; guillain-barre.
. 2022 Feb 16;14(2):e22290.
doi: 10.7759/cureus.22290. eCollection 2022 Feb.
COVID-19-Associated Autoimmune Disease: A Rare First Case Report of Acute Motor Axonal Neuropathy Variant of Guillain-Barre Syndrome in a Woman Patient in New York City
Zaheer Qureshi[SUP] 1 2 [/SUP], Sameer Kandhi[SUP] 2 [/SUP], Neeti Prasai[SUP] 2 [/SUP], Faryal Altaf[SUP] 2 [/SUP], Manjeet Dhallu[SUP] 3 [/SUP]
Affiliations
- PMID: 35350485
- PMCID: PMC8933148
- DOI: 10.7759/cureus.22290
Abstract
Novel outbreaks with COVID-19 can cause multiple systemic manifestations, including autoimmune disease. Among all the infections, respiratory complications are the most apparent symptoms. Guillain-Barre syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy often related to previous infectious exposure. GBS emerged as a potentially severe complication of coronavirus disease 2019 (COVID-19) since its declaration as a global pandemic. We report the first case of COVID-19-induced acute motor axonal neuropathy variant of Guillain-Barre syndrome (GBS) from New York, USA. Our patient was a 66-year-old woman who had recently tested positive for COVID-19 and presented with bilateral upper and lower extremity weakness. Electromyogram studies showed acute demyelinating polyradiculoneuropathy. She was diagnosed with an acute motor axonal neuropathy variant of GBS. She was successfully treated with intravenous immunoglobulins (IVIGs) with marked improvement. In six months, she regained her strength back to normal. Whether GBS incidence in COVID-positive patients is based on molecular mimicry or anti-ganglioside antibodies is unclear. Physicians should be aware of GBS as a potentially serious complication associated with COVID-19. Further investigations and trials should be conducted better to understand the mechanism of GBS in patients of COVID-19.
Keywords: autoimmune; axonal neuropathy; coronavirus; covid-19; guillain-barre.